Gemphire Therapeutics Inc (NASDAQ: GEMP) Stock Coverage Initiated at Jefferies Group

Analysts at Jefferies Group initiated coverage on Gemphire Therapeutics Inc (NASDAQ: GEMP) stock, starting the company at Buy and a price target of $15.00. As a means of comparison, a number of other analysts have commented on the stock recently, and the company has earned a consensus one-year price target of $19.00, $10.49. Gemphire Therapeutics Incstock has a 52-week high of $11.98.

Stock suffered moderate losses yesterday across the board on the heels of Monday’s gains.

The Dow Jones Industrial Average lost 49 points, or 0.26 percent, to close at 18,454.The S&P 500 shed 4 points, or 0.20 percent, to finish at 2,176.The Nasdaq lost 9 points, or 0.18 percent, to close at 5,223.

NYMEX crude oil futures lost 1.21 percent to $46.41 while Brent contracts shed 1.64 percent and were last trading at $48.45.

Share prices sometimes get a bounce to the upside when analysts inititate coverage.

Shares of Gemphire Therapeutics Inc (NASDAQ: GEMP) opened at $10.49 and traded in a range between, $10.40 and $11.98 yesterday, and last traded at $11.30, which represents a change of $ 1.15 over the previous closing price.

Gemphire Therapeutics Inc (NASDAQ: GEMP) currently has a market cap of 42.47M

The stocks average daily volume is 41,794 shares out of a total float 1,439,000 of and some 184,250 shares crossed the trading desk yesterday, 100 percent higher than normal. Significant increases in trading volume and price appreciation together could signal heavy volume accumulation by institutional investors.

While increased trading for short periods will not mean much will not mean much, conversely, a trend of heavy trading volume on the buy side over a period of days or weeks sends a positive signal to market traders that institutions may be moving in, so institutional sponsorship is very important.

Institutional sponsorship simply refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These instituitional investors have teams of analysts researching thousands of stocks, so it is good confirmation to see them taking a postion in a stock you are researching.

By tracking the activity of these professional investors—and the moving averages they affect—it allows for traders to make more effective decisions on trades.

With that in mind Gemphire Therapeutics Inc (NASDAQ: GEMP) now has a 50-day MA is $9.87 and 200-day MA is $9.87, and it has traded in a 52-week range between $8.80 – 11.98 and today’s last price is -5.68 percent off the 52 week high.

Indeed, earnings growth is among the most important things to look in regards to stock investing and, accordingly, investors seek companies who have been successful at growing their earnings by at least 25 percent over a 3 year period.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of BNB Daily News. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.